References: Excess body weight, obesity and atherosclerotic cardiovascular disease risk

Meany G, Conceicao E, Mitchell JE. Binge eating, binge eating disorder and loss of control eating: effects on weight outcomes after bariatric surgery. Eur Eat Disord Rev 2014;22(2):87-91. https://www.ncbi.nlm.nih.gov/pubmed/24347539
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-44. https://www.ncbi.nlm.nih.gov/pubmed/27633186
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375(4):311-22. https://www.ncbi.nlm.nih.gov/pubmed/27295427
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 2017;3(1):3-14. https://www.ncbi.nlm.nih.gov/pubmed/28392927
Smith MD, Patterson E, Wahed AS, Belle SH, Berk PD, Courcoulas AP, et al. Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg 2011;21(11):1687-92. https://www.ncbi.nlm.nih.gov/pubmed/21866378
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. https://www.ncbi.nlm.nih.gov/pubmed/33567185
World Health Organization (WHO). Waist circumference and waist–hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. Geneva: WHO Press; 2011. https://www.who.int/publications/i/item/9789241501491